Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Kalvista has received approval for the first on-demand hereditary angioedema pill after facing challenges with the FDA. Meanwhile, Robert F. Kennedy Jr. has made significant cuts and rehires at the Department of Health and Human Services. Upcoming biopharma milestones to watch include developments in obesity and rare genetic diseases, as well as therapies targeting the TIGIT space. Drug developers are exploring digitization strategies to optimize processes and embrace technology in the development journey amidst a busy buyout period in the pharmaceutical industry.Transitioning to the next news, the text discusses four therapies targeting TIGIT that are still holding on in a troubled space where many others have failed. It also highlights the potential of using AI and genetics to reduce adverse drug reactions and restore public trust in the pharmaceutical industry. Additionally, it mentions the FDA's decision to remove risk evaluation and mitigation strategies for certain cell and gene therapies, as well as recent developments in ultrarare therapies, cancer treatments, and regulatory changes. The text provides information on the HHS overhaul by the numbers, including rehiring hundreds of employees but still operating with reduced staff.

Support the show